This document discusses definitions, classifications, and clinical applications of acute kidney injury (AKI) according to KDIGO guidelines from 2012. It defines AKI as an increase in serum creatinine of ≥0.3 mg/dL within 48 hours or an increase to ≥1.5 times baseline within 7 days. AKI is staged from 1 to 3 based on increases in creatinine from baseline or reductions in urine output. Proper estimation of baseline creatinine and clinical judgment are important for accurate diagnosis and staging. Pseudo-AKI and atypical cases may not meet diagnostic criteria but still represent kidney injury.
Renal Replacement Therapy: modes and evidenceMohd Saif Khan
Renal replacement therapy is a supportive care often required in critically ill patients who develop acute renal failure and its complications. Complexity arises when such patients become hemodynamically unstable and pose special challenge to critical care clinicians in ICU to carefully choose dialytic modality to tackle volume and solute overload. This presentation is about short description of modalities of RRT and current evidence regarding initiation, dose and type of modality.
Renal Replacement Therapy: modes and evidenceMohd Saif Khan
Renal replacement therapy is a supportive care often required in critically ill patients who develop acute renal failure and its complications. Complexity arises when such patients become hemodynamically unstable and pose special challenge to critical care clinicians in ICU to carefully choose dialytic modality to tackle volume and solute overload. This presentation is about short description of modalities of RRT and current evidence regarding initiation, dose and type of modality.
Dose Adjustment in Renal Failure ...Practical Approach for Clinical Pharmacists to help them perfectly adjust doses for medications according to best evidence to date
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Performance Standards for Antimicrobial Susceptibility Testing
AKI 2023.pptx
1. ACUTE KIDNEY INJURY:
DEFINITIONS, CLASSIFICATIONS AND
CLINICAL APPLICATION
(KDIGO GUIDELINES 2012 SECTION
2)
Presentor : Dr. Sunit kasar
Moderater: Dr. Jitendra Singh Chahar
2. DEFINITION
• AKD – alterations in kidney structure and function for
< 3 months, which may precede CKD or may be
superimposed on CKD, with duration up to 3 months
• AKI – a subgroup of AKD, defined by alterations in
kidney function over 6 hours to 1 week
• CKD – alterations in kidney structure and function for
>3 months
7. DEFINITION OF
AKI (KDIGO 2012)
●Increase in serum creatinine by ≥0.3 mg/dL (≥26.5
micromol/L) within 48 hours, or
●Increase in serum creatinine to ≥1.5 times baseline,
which is known or presumed to have occurred within
the prior 7 days, or
●Urine volume <0.5 mL/kg/hour for six hours
8.
9. DIFFERENCE BETWEEN PRE RENAL &
RENAL AKI
PRE RENAL INTRINSIC
MEASUREMENT PRE RENAL RENAL
DISORDER
URINE SODIUM < 20 mEq/L > 40
FE Na < 1 % > 2 %
FE Urea < 35 % > 50 %
Urine
OSMOLALITY
> 500 m Osm/Kg 300-400
mOsm/Kg
Urine/Plasma
OSMOLALITY
> 1.5 1-1.3
14. • case A can be diagnosed with AKI on day 2 by the first
criterion, whereas the second criterion is not satisfied until day
3 (increase from 1.3 to 2.0).
• If creatinine measurements had been available 48 hours prior
to day 1 and if this level had been at baseline (1.0 mg/dl [88.4
mmol/l]), it would have been possible to diagnose AKI on day 1
using the second criterion.
• If Case A had not presented to medical attention (or if SCr had
not been checked) until day 7, the case of AKI would likely
have been missed.
15. • Case B illustrates why criterion 2 can detect cases of
AKI missed by criterion 1. It also clarifies why these
cases are unusual.
• Had the SCr increased to 1.5 mg/dl as opposed to
peaking at 1.4 mg/dl, it would have been picked up
by criterion 1 as well.
B 1.0 1.1 1.2 1.4 1.0 No . Yes
16. • Cases C, D, and even F illustrate how criterion 2 may
miss cases identified by criterion 1.
C 0.4 0.5 0.6 0.7 0.4 Yes No
D 1.0 1.1 1.2 1.3 1.5 Yes No
F ? 3.0 2.6 2.2 1.0. Yes No
17. • Cases F-H do not have a baseline measurement of
SCr available.
• Elevated SCr (reduced eGFR) on day 1 of the
hospitalization is consistent with either CKD or AKD
without AKI.
• In Case F, baseline SCr can be inferred to be below
the day 1 value because of the subsequent clinical
course; thus, we can infer the patient has had an
episode of AKI.
18. • In case G, AKI can be diagnosed by application of
criterion 2, but the patient may have underlying CKD.
G ? 1.8 2.0 2.2 1.6 ? Yes
19. • Case H does not fulfill the definition for AKI based on
either criteria, and has either CKD or AKD without
AKI.
H. ? 3.0 3.1 3.0 2.9 ? No
20. ESTIMATING BASELINE CREATININE
• Many patients will present with AKI without a reliable
baseline SCr on record
• Baseline SCr can be estimated using the Modification
of Diet in Renal Disease (MDRD) Study equation
assuming that baseline eGFR is 75 ml/min per 1.73
m2
21.
22. APPLICATION OF AKI STAGES
• Once a diagnosis of AKI has been made, the next
step is to stage it.
• Like diagnosis, staging requires reference to a
baseline SCr when SCr criteria are used.
23. KDIGO STAGING 2012
STAGES CREATININE URINE OUTPUT
1 ≥0.3 mg/dl increase
1.5 to 1.9 times the BASELINE
< 0.5 ml/kg/hour for 6-12 hours
2 2.0 to 2.9 times the BASELINE <0.5 ml/kg/hour for ≥12 hours
3 3.0 times the BASELINE .
Creatinine ≥4.0 mg/ dl
Patient on RRT
In < 18yrs age – eGFR <
35ml/min/1.73 m2
< 0.3 ml/kg/hour for ≥24 hours
ANURIA for ≥12 hours
24.
25. STAGING FOR CASE A
The maximum stage is 2 because reference SCr is 1.0
mg/dl and the maximum SCr is 2.0 mg/dl
Had the reference SCr been 0.6 mg/dl, the maximum stage
would have been 3.
26. STAGING FOR CASE F
• Case F was staged by using the lowest SCr (1.0
mg/dl ) as the reference.
• The actual baseline for this case might have been
lower but this would not affect the stage, since it is
already stage 3
F ? 3.0 2.6 2.2 1.0 1.0 3
27. • Cases G and H can only be staged if the reference
SCr can be inferred.
• Case G may be as mild as stage 1 if the baseline is
equal to the nadir SCr on day 7.
G ? 1.8 2.0 2.2 1.6 ? >1
H ? 3.0 3.1 3.0 2.9 ? ?
28. URINE OUTPUT VS. SCR
• Both urine output and SCr are used as measures of an acute change in
GFR.
• The advantage of urine output over SCr is the speed of the response.
• For e.g if GFR were to suddenly fall to zero, a rise in SCr would not be
detectable for several hours. On the other hand, urine output would be
affected immediately.
• Less is known about the use of urine output for diagnosis and staging
compared to SCr, since administrative databases usually do not capture
urine output (and frequently it is not even measured, especially outside
the ICU).
29. • Studies using both SCr and urine output to diagnose AKI show
increased incidence, suggesting that the use of SCr alone may
miss many patients.
• The use of urine output criteria (criterion 3) will also reduce the
number of cases where criterion 1 and criterion 2 are discordant
(cases B,C,D, and F ), as many of these cases will be picked up
by urine output criteria.
URINE OUTPUT VS. SCR
30. PSEUDO-AKI.
• The most obvious example is with laboratory errors or errors in
reporting. Erroneous laboratory values should obviously not be
used to diagnose disease and suspicious lab results should
always be repeated.
• Daily variation in SCr due to differences in diet and activity may
be as great as 10%
• Endogenous chromogens (e.g., bilirubin, ascorbic acid, uric acid)
and exogenous chromogens and drugs (e.g., cephalosporins,
trimethoprim, cimetidine) may interfere with the creatinine assay.
• The cumulative effect of these various factors influencing
precision, bias, and biological variation may approach the level at
which it could impact the diagnosis of AKI.
31. • Finally, a weight-based criterion for urine output will
mean that some very obese patients will fulfill the
definition of AKI without any kidney abnormality.
• Clinical judgment should always be exercised in
interpreting such data.
PSEUDO-AKI.
32. ATYPICAL AKI
• The situation where a case of AKI fails to meet the definition.
These cases should be distinguished from conditions in which
data are simply missing and/or refer to situations in which existing
data are unreliable.
• For example, a patient might receive very large quantities of
intravascular fluids such that SCr is falsely lowered.
• Similarly, massive blood transfusions will result in the SCr more
closely reflecting the kidney function of the blood donors than the
patient.
33. • Changes in creatinine production are also well known
in conditions such as muscle breakdown where
production increases and in muscle wasting (including
advanced liver disease) where production is
decreased.
• Creatinine production may also be decreased in
sepsis possibly due to decreased muscle perfusion.
ATYPICAL AKI
34.
35. CLINICAL JUDGMENT
• While the definitions and classification system discussed in guidelines provide a
framework for the clinical diagnosis of AKI, they should not be interpreted to
replace or to exclude clinical judgment
• While the vast majority of cases will fit both AKI diagnostic criteria as well as
clinical judgment, AKI is still a clinical diagnosis.
• Not all cases of AKI will fit within the proposed definition and not all cases fitting
the definition should be diagnosed as AKI. However, exceptions should be very
rare.